Rituximab biosimilar(Protheragen)

N/A

Report date: 2025/03/07 17:34:23

Base Information

Drug NameRituximab biosimilar(Protheragen)
Drug Alias NameProS-04
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A